For comparison, Forxiga (known as Farxiga in the US) was shown in the DAPA-CKD to cut by 39% the risk of kidney disease progression, or death from kidney or cardiovascular causes. The new approval ...
If the EMA follows the CHMP’s advice, Zynquista will become the second SGLT-acting drug to be approved for use alongside insulin in type 1 diabetes after AstraZeneca’s SGLT2 inhibitor Forxiga ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback